Dozens of unscrupulous web-based sellers of glucagon-like peptide-1 agonists are evading FDA scrutiny and patient safety controls to hawk GLP-1 weight-loss medications outside of the legitimate prescription drug supply chain, according to a new research-based editorial in Annals of Pharmacotherapy.
The paper, by pharmacist researchers from the University of Connecticut School of Pharmacy in Storrs, identifies at least 40 sites that market vials of lyophilized semaglutide and